[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 14, Issue 3 (Summer 2023) ::
Caspian J Intern Med 2023, 14(3): 543-552 Back to browse issues page
N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study
Siamak Afaghi * , Negin Moghimi , Nasser Malekpour Alamdari , Fatemeh Sadat Rahimi , Rana Irilouzadian , Farzad Esmaeili Tarki , Morvarid Moghimi , Sara Beshaarat , Hossein Salehi Omran , Anita Karimi
Research Institute of Internal Medicine, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran , siamak.afaghi@sbmu.ac.ir
Abstract:   (578 Views)
Background: Whilst over two years have passed since the COVID-19 pandemic's emergence, the proper management of the disease remains challenging. N-acetylcysteine (NAC) as a potentially effective therapeutic option has been suggested by studies, while the exact clinical role of this agent is yet to be evaluated.
Methods: This prospective case-control study was conducted in a major referral respiratory center in Tehran, Iran. We enrolled 217 patients treated with an intravenous daily dose of 1500 mg NAC as a case group; and 245 control patients who did not receive NAC. Two groups were matched based on other treatments, socio-demographics, medical history, and comorbidities.
Results: After ten days of adjuvant therapy with NAC, patients in the NAC group and control group had median room-air SpO2 of 91% and 88%, respectively (P=0.02). Also, the SpO2 to FiO2 ratio had a median of 463 and 421 in the case and control groups, respectively (P=0.01). Furthermore, the case group's hospitalization period was three days shorter (P=0.002). Further, cough, dyspnea, and decreased appetite were reported to have a significantly lower incidence in the case group (P=0.03, 0.001, 0.008).
Conclusion: We showed that a daily intravenous dose of NAC in hospitalized COVID-19 patients could shorten the hospital stay and improve some clinical symptoms; however, it does not remarkably improve the risk of ICU admission and the 28 days in-hospital mortality rate.

Keywords: N-acetylcysteine, antioxidant, SARS-Cov-2, COVID-19, mortality
Full-Text [PDF 287 kb]   (404 Downloads)    
Type of Study: Original Article | Subject: Internal
Received: 2022/02/24 | Accepted: 2022/10/29 | Published: 2023/05/9
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Afaghi S, Moghimi N, Malekpour Alamdari N, Rahimi F S, Irilouzadian R, Esmaeili Tarki F, et al . N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study. Caspian J Intern Med 2023; 14 (3) :543-552
URL: http://caspjim.com/article-1-3389-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 3 (Summer 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 30 queries by YEKTAWEB 4570